Although failed to achieve, a durable antitumor activity to atezolizumab was observed in a subset of penile cancer.
Single-center, PhII study 32 treated w/ atezolizumab; 20 received additional RT: 1-y PFS (goal 35%)
RESULTs:
Median FU 29 m
Median OS was 11.3 m
1-yPFS 12.5 %
ORR 16.7% w/ 2 complete and 3 partial responders
PFS in hrHPV + tumors & high T cell infiltration